Thermo Fisher Scientific
This webinar focuses on development and validation of proteomics-based oncology biomarkers using peptide surrogates. A descriptive overview is provided for the assay development pipeline utilized to bring proteomics markers from targeted-discovery experiments to multiplexed SRM methods, with validated methods translated into the CAP-CLIA lab.
For Research Use Only. Not for use in diagnostic procedures.
Todd Hembrough, PhD, President of Proteomics, NantOmics
Todd Hembrough, PhD is the President, Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he helped lead the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
Maryann Vogelsang, PhD, Manager, Assay Development, NantOmics
Maryann Vogelsang, PhD leads the assay development team, and drives the implementation and delivery of NantOmics’ mass spectrometry (MS)-based assay development pipeline for both R&D and clinical proteomics laboratories. Maryann earned her PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles. Prior to NantOmics, Maryann established a CLIA compliant laboratory that offered both ELISA- and MS-based clinical assays. She has over a decade of experience in translational medicine utilizing the mass spectrometry platform, and spent a significant part of her career as a scientist developing workflows that facilitate proteomics biomarker discovery and validation processes at the Thermo Fisher Scientific BRIMS Center.
* Required field